Conferences ramp up, and ASH abstracts near.

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

The company reckons it’s got what it takes to hit the right member of the FGFR family.